

# PharmaBoardroom Releases Mexico Pharmaceuticals Report

Pharmaboardroom today releases its new 98-page Mexico Healthcare and Life Sciences Report 2015.

LONDON, UNITED KINGDOM, November 23, 2015 /EINPresswire.com/ -- Pharmaboardroom today releases its new 98-page [Mexico Healthcare and Life Sciences Report 2015](#).

It offers companies, investors, policymakers, and stakeholders with an interest in healthcare, pharmaceuticals, or life sciences insights into the second largest pharma and healthcare market in Latin America, a country of over 122 million people.

It features interviews with senior executives from the major companies in [Mexico](#) and leaders of the country's most important institutions, updated facts and figures on Mexico's healthcare and pharma sectors, and feature stories.

The report is an authoritative assessment of a fast-growing sector in a country likely to continue receiving a great deal of investment in the years and decades

ahead, for the following reasons:

Reform - The Mexican government has committed to turn Mexico from a manufacturing to an innovation-centric economy, with healthcare as a key driver. For example, the recent opening of the Mexican Social Security Institute to clinical research will to open the country up to more innovation.

“

Competition is fierce, but the market as well as the regulatory framework in place provide the necessary certainty to keep investing in Mexico.

*Ugo de Jacobis, president - AstraZeneca Mexico*

International Recognition - Mexico's regulatory authority, Cofepris, has been recognized as a National Regulatory Authority of Regional Reference for medicines and biological products by the Pan-American Health Organization and as a Functional Regulatory Agency for vaccines by the World Health Organization.

Increased Coverage - In the last decade, Mexico has moved rapidly towards universal healthcare coverage. The number of

interventions covered by Seguro Popular has increased threefold in the last decade, the amount of drugs included more than 300 percent, and the number of diseases included in the 'fund for protection



against catastrophic expenditures' raised from 4 to 59.

The Mexico Healthcare and Life Sciences Report 2015 includes features and articles on:

Industry Trends including Mexico's strength in genomics, decreasing approval times, innovation, foreign companies in Mexico, generics, manufacturing costs, multinationals, biotech, the Mexican medical devices industry, pharmacies offering medical consultation, and physicians at the point of sale, third party logistics

Institutions and Reforms including Cofepris - Mexico's Regulator, Mexico's Healthcare System, Social Security System, and drive towards Universal Healthcare Coverage.

Healthcare Trends including the rise of the non-communicable disease, access challenges, the battle against rare diseases, and mental health in Mexico,

Macroeconomic and legal trends such as the market outlook and intellectual property in Mexico  
Interviews

The report also includes interviews with:

Julio Frenk, Harvard TH Chan School of Public Health

Rafael Gual, Canifarma

Cristobál Thompson, AMIIF

Roberto Tapia, Carlos Slim Foundation

Alexis Serlin, Novartis Mexico

José Alarcón Irigoyen, PriceWaterhouseCoopers

Juan Knobloch, Knobloch Information Group

Fabiola Trigueros, Smart Scale

Mark Stoffels, Philips Healthcare Mexico

Teresa Corona Vazquez, Instituto Nacional de Neurología y Neurocirugía

Juan Ángeles Uribe, Carnot

Sonia Mayra Pérez Tapia, Udimeb

Mauricio Bravo, Tornel

Dominik Bacher, director of Bacher Zoppi

Alfredo Gutierrez, Anfitriones

Quotes

"Competition is fierce, but the market as well as the regulatory framework in place provide the necessary certainty to keep investing in Mexico." - Ugo de Jacobis, president and general director of AstraZeneca Mexic

"The main reasons that lead the company to pick Mexico over other countries is the strong commitment of the Mexican government to public health, and specifically to vaccination." - Eduardo Arce Parellada, Sanofi Pasteur Mexico

"We support increased participation of the private sector in the health sector through outsourcing of services and public-private partnerships. But there are still many questions about how this should happen." - José Campillo, President of the Mexican Health Foundation (Funsalud)

"Mexican drug manufacturers are investing in the country and are fighting for it, and this should be recognized at national and international level." - Alfredo Rimoch, general director

of Liomont

Michael Comi  
Focus Reports  
+44 1707 828 754  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.